According to the reports that MYC drove the SCLC-N and SCLC-Y subtype of SCLC in a temporal evolution by reprograming neuroendocrine fate [25], SCLC-N cell lines highly expressed c-Myc with low level of NKG2DL and showed less immune infiltrate than other types [26], and SCLC-Y cell lines expressed low level of c-Myc with high level of NKG2DL [8], we speculated that MYC may contribute to the construction of SCLC-N immune microenvironment and the effect of immunotherapy through modulating NKG2DL. Here, MYC is linked to small cell lung carcinoma.